Pharmaceuticals Stocks

Johnson & Johnson Quarterly Valuation – November 2014 $JNJ

500px-JohnsonandJohnsonLogo.svgJohnson & Johnson is suitable for the Enterprising Investor but not the Defensive Investor, who is concerned with the high PEmg and PB ratios. The Enterprising Investor, on the other hand, has no initial concerns with the company. As a result, the Enterprising Investor should feel very comfortable proceeding to the next part of the analysis, which is a determination of the company’s intrinsic value.

From a valuation side of things, the company has grown its EPSmg (normalized earnings) from $4.41 in 2010 to only an estimated $4.81 for 2014. This demonstrated growth does not support the market’s implied estimate of 6.87%. In fact, the demonstrated growth over the last several years is only 1.79% per year. The company would have to see a significant change in its level of growth in order to meet the market’s estimated growth level. As a result, the ModernGraham valuation model returns an estimate of intrinsic value below the market price at this time, and the company appears to be overvalued by the market.

Be sure to check out previous ModernGraham valuations of Johnson & Johnsonfor better perspective.

Read the full valuation on Seeking Alpha!

JNJ Chart

JNJ data by YCharts

Disclaimer:  The author did not hold a position in Johnson & Johnson (JNJ) or in any other company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  Logo taken from Wikipedia for the sole purpose of identifying the company; this article is not affiliated with the company in any manner.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back To Top